Similar to the parent m276 mAb, this ADC demonstrates high-affinity binding to both human and mouse CD276 (KD 29 and 24 nM for hCD276 and mCD276, respectively) and, in preclinical tumor studies, displayed minimal toxicities at doses that proved highly efficacious. Here, CD276 is linked to neoplasm.